Moxonidine

Bezeichnung:Moxonidine

Englisch Name:Moxonidine

CBNumberCB8121013

SummenformelC9H12ClN5O

Molgewicht241.68

Moxonidine physikalisch-chemischer Eigenschaften

Schmelzpunkt	217-219° (dec)
Siedepunkt	364.7±52.0 °C(Predicted)
Dichte	1.52±0.1 g/cm3(Predicted)
storage temp.	2-8°C
Löslichkeit	Very slightly soluble in water, sparingly soluble in methanol, slightly soluble in methylene chloride, very slightly soluble in acetonitrile.
Aggregatzustand	Solid
pka	7.11±0.10(Predicted)
Farbe	White to Almost white
Wasserlöslichkeit	800.3mg/L(temperature not stated)
Merck	14,6293
InChIKey	WPNJAUFVNXKLIM-UHFFFAOYSA-N
CAS Datenbank	75438-57-2(CAS DataBase Reference)

Sicherheit

Gefahreninformationscode (GHS)

Beschreibung
Moxonidine, which is structurally related to clonidine, is a new centrally acting antihypertensive that acts as a stronger agonist at imidazole receptors and a weaker agonist at α2-adrenergic receptors than clonidine. It is also reported to have less side effects and a much reduced potential to produce a rebound in blood pressure on withdrawal. Clinically, moxonidine appears to have comparable antihypertensive efficacy with the ACE inhibitors and calcium antagonists.
Chemische Eigenschaften
White Solid
Originator
Beiersdorf (Germany)
Verwenden
Antihypertensive;Imidazoline receptor agonist
Verwenden
Moxonidine is an antihypertensive agent.
Definition
ChEBI: Moxonidine is an organohalogen compound and a member of pyrimidines.
Trademarks
Cynt (Lilly); Nucynt (Lilly); Norcynt (Lilly);Physiotens.
Biologische Aktivität
Mixed I 1 imidazoline receptor and α 2 -adrenergic agonist; displays 40-fold higher affinity for I 1 receptors versus α 2 -adrenoceptors. Centrally acting antihypertensive agent.
Clinical Use
Antihypertensive agent (centrally acting agonist at I1 receptor, imidazoline and alpha2 adrenoceptors)
Stoffwechsel
10-20% metabolised, predominantly to 4,5-dehydromoxonidine and to an aminomethanamidine derivative both of which are much less active than moxonidine. Moxonidine and its metabolites are almost entirely eliminated via the kidney. More than 90% of the dose is eliminated in the first 24 hours via the kidney, while approximately 1% is eliminated in the faeces